Form 4: Talis Biomedical Corp: Director Leonard Braden Michael Increases Stake

Director Leonard Braden Michael reports purchasing 151 shares of Talis Biomedical Corp at $4.25 on August 30, 2024, increasing his indirect holdings.

Summary

• On August 30, 2024, Leonard Braden Michael, a director of Talis Biomedical Corp, acquired 151 shares of common stock at a price of $4.25 per share.
• The transaction increased his indirect beneficial ownership to 218,602 shares, held through BML Investment Partners, L.P.
• BML Capital Management, LLC, where Mr. Leonard is the managing member, serves as the general partner of BML Investment Partners, L.P.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a standard disclosure of a stock purchase by a director. It doesn't inherently indicate positive or negative sentiment about the company's performance.

Positives

• A director's purchase of shares can be seen as a positive signal, indicating confidence in the company's future prospects.

Management Comments

• Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.

Industry Context

This filing is a routine disclosure required by the SEC for corporate insiders, providing transparency to the market regarding their transactions in the company's stock.

Key Dates

Keywords

Talis Biomedical Corp, Leonard Braden Michael, stock purchase, beneficial ownership, director, TLIS, BML Investment Partners, BML Capital Management